Equity Incentive Plans and Stock-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2022

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Summary of Stock Option Activity and Activity Regarding Shares Available for Grant

Stock option activity and activity regarding shares available for grant under the 2021 Plan is as follows:

	Options Outstanding
	Outstanding Stock Options			Weighted-Average Exercise Price			Weighted-Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
	(in thousands, except share, years, and per share data)
Balance as of March 31, 2021		29,375,026		$	9.37		7.1		$	403,498
Recapitalization		38,002,437		$	(5.28	)
Balance as of March 31, 2021		67,377,463		$	4.09
Granted		14,968,952		$	4.37
Exercised		(5,808,526	)	$	2.90
Cancelled/Forfeited/Expired		(2,928,324	)	$	4.80
Balance as of March 31, 2022		73,609,565		$	4.21			6.9	$	35,979
Vested and exercisable as of March 31, 2022		42,902,557		$	3.84			5.6	$	27,504

Schedule of Assumptions Used in the Black-Scholes Option-Pricing Model

The Black-Scholes assumptions used to value stock options at the grant dates are as follows:

	Year Ended March 31,
	2022						2021						2020
	Min			Max			Min			Max			Min			Max
Expected term (years)		3.3			6.1			4.0			6.1			5.0			6.1
Expected volatility		72	%		75	%		61	%		68	%		53	%		62	%
Risk-free interest rate		1.0	%		2.5	%		0.2	%		0.5	%		0.6	%		2.2	%
Expected dividend yield		0	%		0	%		0	%		0	%		0	%		0	%

Summary of Restricted Stock Awards Activity under the Equity Incentive Plan

The following table summarizes the RSU activity under the equity incentive plans and related information:

	RSUs
	Unvested RSUs			Weighted-Average Grant Date Fair Value Per Share
Balance as of March 31, 2021		—			—
Granted		11,943,645		$	9.83
Vested		(801,794	)	$	10.90
Cancelled/forfeited		(465,473	)	$	11.08
Balance as of March 31, 2022		10,676,378		$	9.70

Schedule of Share Based Compensation Costs

The total share-based compensation expense related to stock options by line item in the accompanying consolidated statements of operations and comprehensive loss is summarized as follows:

	Year Ended March 31,
	2022		2021		2020
	(in thousands)
Cost of revenue	$	4,029	$	858	$	733
Research and development		26,540		21,771		16,524
Sales and marketing		5,122		4,081		3,988
General and administrative		22,242		59,986		18,932
Restructuring and other charges	—			—		881
Total stock-based compensation expense	$	57,933	$	86,696	$	41,058